Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Assessment of Endothelial Function, Apolipoproteins and Adiponectin Levels as Markers of Cardiovascular Before and After Liver Transplantation

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Kymberly D. Watt, Mayo Clinic Identifier:
First received: February 17, 2011
Last updated: January 21, 2014
Last verified: January 2014

The overall hypothesis is that endothelial function, apolipoprotein levels and adiponectin levels are accurate predictors of underlying cardiovascular disease in patients with end-stage liver disease, in whom standard tools for the diagnosis of and screening for cardiovascular disease are of limited utility.

Condition Phase
Phase 0

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Assessment of Endothelial Function, Apolipoproteins, and Adiponectin Levels as Markers of Cardiovascular Before and After Liver Transplantation

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Endothelial dysfunction in cirrhotic liver transplant candidates up to one year after transplant. [ Time Frame: one year posttransplant ] [ Designated as safety issue: No ]
    Endothelial function testing will be performed by reactive hyperemia peripheral artery tonometry in consecutive patients ≥21 years old awaiting liver transplantation and repeated at 3 weeks, 4 months and 1 year post transplantation

Secondary Outcome Measures:
  • Metabolic abnormalities and cardiovascular disease by endothelial dysfunction and blood testing up to one year pre-transplant [ Time Frame: 1 year posttransplant ] [ Designated as safety issue: No ]
    Endothelial dysfunction testing, apolipoproteins and adiponectin levels will be performed prior to liver transplantation and repeated at 3 weeks (endothelial dysfunction only), 4 months and 1 year post transplantation. Pre transplant results will be analyzed for association with perioperative cardiovascular events. In addition, post transplant endothelial dysfunction results (and the delta change) along with adiponectin levels will be analyzed for cardiovascular event endpoints by 1 year post transplant.

Biospecimen Retention:   Samples Without DNA

Serum samples will be retained for future liver transplant research.

Estimated Enrollment: 200
Study Start Date: June 2011
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
End-stage liver disease awaiting transplant
Patients with end-stage liver disease (non-fulminant) awaiting liver transplant


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cirrhotic end-stage liver disease awaiting transplant


Inclusion Criteria:

  • Greater than or equal to 21 years of age.
  • Cirrhotic end-stage liver disease
  • Pre-transplant

Exclusion Criteria:

  • Dialysis shunt
  • non-cirrhotic liver disease
  • fulminant hepatic failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01300390

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Kymberly Watt, MD Mayo Clinic
  More Information


Responsible Party: Kymberly D. Watt, M.D., Mayo Clinic Identifier: NCT01300390     History of Changes
Other Study ID Numbers: 10-008776
Study First Received: February 17, 2011
Last Updated: January 21, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
liver transplant
end-stage liver disease
cirrhosis processed this record on March 03, 2015